Category Archives: Immunology

Exercise and the immune Response – Edgefieldadvertiser

By Paul Gustafson, PhD, RKT, RPG Kinesiotherapy, LLC, Edgefield, SC

In recent weeks there has been an increased interest in methods to protect oneself from infection. Reducing ones exposure to infection has recently been a priority in our minds and in media reports. Another topic receiving somewhat less but important attention is that of maintaining and enhancing ones immune response to infection. Our immune system uses cells of various types as warriors to resist or combat infections and chronic disease. There is evidence that a regular exercise program can enhance the performance of our immune system (5).

It has been known for some time that cardiorespiratory exercise, also known as aerobic exercise, can enhance the performance of our immune system (5) by increasing the numbers of some of the cellular warriors to one degree or another. Activities using large muscle groups, performing large limb movements, performed rhythmically for an extended period of time can qualify as cardiorespiratory exercise.

More recently, resistance training (strength training) has also been shown to enhance the performance of the immune system in women with breast cancer (3). Ultra-high intensity resistance training is not necessary to increase the numbers of some of the cellular warriors of the immune system. In fact there is some debate regarding evidence that exercise of ultra-high intensity may temporarily suppress the immune system in highly trained, elite athletes (4). Regardless of the outcome of that debate, there is significant agreement in the scientific community that regular bouts of moderate to vigorous intensity exercise will assist the immune system to function properly and will help to lower the risk of respiratory illness/infection and some cancers (4). Exercise routines found successful in sedentary or moderately active individuals may not translate to highly trained, elite athletes (6).

Before beginning an exercise program ones physician should be consulted. The American College of Sports Medicine (ACSM) recommends 150-300 minutes per week of moderate-intensity aerobic physical activity and 2 sessions per week of strength training. There are indoor and outdoor activities that may be used to meet the ACSM guidelines (1). In order to maintain immune health one should begin with an easily tolerated intensity and gradually increase the intensity over a period of weeks. Adding variety of activity will assist in decreasing the monotony of the exercise routine (6). The ACSM offers a list of specific activities one can use to meet their guidelines. There are also frequently asked questions with reference to COVID-19 addressed on their website as well (1).

Exercise is not the only variable that can affect the immune system. Factors such as potential exposure to disease causing organisms, health status, lifestyle behaviors, sleep and recovery, nutrition and psychosocial issues also play a role (4, 6). In 2007 The ACSM along with the American Medical Association (AMA) co-launched the Exercise is Medicine (EIM) initiative. The purpose of EIM is to make physical activity assessment and promotion a standard in clinical care (2).

Exercise engagement is something we can immediately control. You are encouraged to follow the lead of the ACSM and AMA and ask your healthcare provider for recommendations regarding exercise in your health maintenance plan.

1. http://acsm.org/read-research/newsroom/news-releases/news-detail/2020/03/16/staying-physically-active-during-covid-19-pandemic

2. https://www.exerciseismedicine.org/support_page.php/about-eim/

3. Hagstrom, AD et al. (2016). The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial. Breast Cancer Research and Treatment, 155: 471-82.

4. Simpson, RJ et al. (2020). Can exercise affect immune function to increase susceptibility to infection? Exercise Immunology Review, 26:8-22.

5. Walsh, NP et al. (2011). Position Statement Part one: Immune function and exercise. Exercise Immunology Review, 17: 6-63. 6. Walsh, NP et al. (2011). Position Statement Part two: Maintaining Immune Health. Exercise Immunology Review, 17: 64-103.

Original post:
Exercise and the immune Response - Edgefieldadvertiser

Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 | Antibodies | News Channels -…

DetailsCategory: AntibodiesPublished on Friday, 03 April 2020 10:50Hits: 300

Amgen Will Leverage Genetics, Immunology, Antibody Engineering and Manufacturing Capabilities

Companies Will Begin Work Immediately

THOUSAND OAKS, CA, and SEATTLE, WA, USA I April 2, 2020 I Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.The mutually exclusive collaboration brings together Adaptive's proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen's expertise in immunology and novel antibody therapy development. Given the rapidly rising incidence of COVID-19 around the world, the companies will begin work immediately and finalize financial details and terms in the coming weeks.

Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and can be given to people who have heightened risk of exposure to SARS-CoV-2, such as healthcare workers.

"Our strong history of collaboration with Adaptive gives us the ability to immediately mobilize our combined resources to help address the urgency in controlling the COVID-19 pandemic. After swiftly obtaining viral gene sequences from hundreds of patients, Amgen was motivated to use theseinsights and quickly pair them with our drug development and manufacturing capabilities. Working with Adaptive and using their viral-neutralizing antibody platform will expedite our ability to bring a promising new medicine into clinical trials as quickly as possible," said Robert A. Bradway, chairman and chief executive officer at Amgen.

Adaptive will extend its high throughput platform to rapidly screen the massive genetic diversity of the B cell receptors from individuals that have recovered from COVID-19. This enables the identification of tens of thousands of naturally occurring antibodies from survivors of COVID-19 to select those that neutralize SARS-CoV-2. Amgen will then leverage its world-class antibody engineering and drug development capabilities to select, develop and manufacture antibodies designed to bind and neutralize SARS-CoV-2. deCODE Genetics, a subsidiary of Amgen located in Iceland, will provide genetic insights from patients who were previously infected with COVID-19.

"We are extremely motivated to join forces with our trusted partner, Amgen, to tackle this global health crisis," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This partnership expands our drug discovery capabilities, demonstrating the power and versatility of our immune medicine platform."

The two companies have signed a Memorandum of Understanding to enable the parties to start work immediately and are planning to execute a Collaboration and License Agreement. Terms of the agreement are not being disclosed. Both companies aim to accelerate the development of a potential antibody against COVID-19 as fast as possible for patients in need.

About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit http://www.amgen.comand follow us on http://www.twitter.com/amgen.

About Adaptive BiotechnologiesAdaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visitadaptivebiotech.comand follow us on http://www.twitter.com/adaptivebiotech.

SOURCE: Amgen

View original post here:
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 | Antibodies | News Channels -...

Are Clinicians Aware of the FDA’s Pregnancy and Lactation Labeling Rule? – Medical Bag

Many women use at least 1 medication during pregnancy. In 2015, the Pregnancy and Lactation Labeling Rule (PLLR) was introduced in order to integrate summaries of the risks of using a particular drug or biologic agent during pregnancy and lactation. However, this system is still not used by clinicians. A study sought to determine clinicians awareness and use of PLLR and the results were published in The Journal of Allergy and Clinical Immunology.

An online survey was developed by the US Food and Drug Administration in collaboration with the American Academy of Allergy, Asthma & Immunology (AAAAI) and conducted in 2018 with the hope of better understanding clinician use of the PLLR. A total of 184 members of the AAAAI who were part of a randomly selected group chose to participate in the survey. Respondents were 66% male, average age 56 years, part of a single or multi-specialty group practice, and treating an average of 2 pregnant women a month. Clinicians were asked whether they were aware of the introduction of the PLLR. Results showed that only 46% of respondents were aware that the narrative summary of risks had replaced the prior letter system, and almost all clinicians said they continued to use the previous system. Most (71%) cited that they had never referred a pregnant patient to a pregnancy exposure registry, but more than half said they would refer patients in the future. A total of 56% of respondents cited that the narrative summary system was too detailed and unclear compared with the letter-based system.

Despite this, many clinicians did find the new narrative summary labeling helpful. Investigators wrote that the most pressing issue identified by the survey was the fact that the majority of clinician respondents were not aware of the PLLR.

There are some study limitations that may help explain this disparity. Many of the respondents were older and treated mostly non-pregnant patients, as well as working in allergy and immunology specialties. A more diverse sample of respondents may yield different results. In addition, a future survey could be useful in understanding why clinicians continue to use the letter system despite the existence of the PLLR.

According to the investigators, the survey reveals a need to educate clinicians in this specialty area on medication risks in pregnancy going forward. This could be met via increased awareness of the new labeling system or development of a multi-product specialty-specific registry.

Reference

Namazy J, Chambers C, Sahin L, et al. Clinicians Perspective of The New Pregnancy and Lactation Labeling Final Rule (PLLR): Results from an AAAAI/FDA Survey [published online February 18, 2020]. J Allergy Clin Immunol Prac [published online February 19, 2020]. doi:https://doi.org/10.1016/j.jaip.2020.01.056

Read the original post:
Are Clinicians Aware of the FDA's Pregnancy and Lactation Labeling Rule? - Medical Bag

What it means to be immunocompromised and the conditions that put you at risk of infection – Business Insider

captionSomeone who is immunocompromised has a higher risk of infection.sourceurbazon/Getty Images

Human bodies are naturally equipped to fight off infections with the help of a complex immune system and infection-fighting white blood cells. However, certain groups have a much harder time warding off infections and staying healthy due to a weakened immune system. This is called being immunocompromised.

Those who are immunocompromised, or sometimes referred to as immunosuppressed, are more vulnerable than the general public to infections caused by viruses, bacteria, fungi, and parasites. On top of this, they are more likely to suffer from serious complications from infections that they pick up.

During epidemics such as what we are experiencing with the COVID-19 outbreak, they are at higher risk for serious illness if they become infected by the virus, says Nicolas Vabret, PhD, assistant professor of Immunology at Mount Sinai in New York City.

If someone is immunocompromised due to a virus, such as HIV, its even harder to fight a secondary infection since the body is already fighting a virus. Thats because the body only has so many infection-fighting white blood cells.

For example, one common problem people with HIV or AIDS may face is pneumonia. According to a 2017 study published in the scientific journal Pneumonia, pneumonia the illlness is one of the most common infections causing morbidity and mortality in those with HIV/AIDS.

Many conditions can cause somebody to become immunocompromised. Some of the most common are:

Aside from diseases, various treatments can cause someone to become immunocompromised. Certain kinds of treatment and therapies, such as anticancer treatments, or treatments received during an organ transplant are also immunosuppressive and can render patients vulnerable to virus infection, says Vabret.

Elderly people are also considered to be immunocompromised, since aging naturally causes the immune system to weaken.

People who are immunocompromised must take extra precautions to protect themselves from illnesses, and the first step to this is living a healthy lifestyle.

Exercise regularly: Staying active and exercising regularly can boost your immune system and may help the body fight infections.

Get enough sleep: According to a 2015 study published in the Journal of Immunology Research, sleep deprivation makes you more susceptible to viral and bacterial infections, so its especially smart for immunocompromised people to get quality sleep. Avoid vices: Vabret also urges immunocompromised people to avoid vices that can weaken the immune system even further, such as smoking, drinking alcohol, and eating excessive junk food.

Eat a healthy diet: Eating a diet rich in vitamins and minerals is critical for maintaining good health. Vitamin C, Vitamin B6, and Vitamin E are great immunity boosters, according to Cleveland Clinic. Its best to get these vitamins (and any other vitamins) through food rather than supplements since your body often absorbs them more easily this way.

Stay clean: Cleanliness is crucial for immunocompromised people. Vabret says they should wash their hands often and thoroughly, avoid touching their face, and clean surfaces in their homes that they touch frequently, especially if these surfaces are shared with other people.

During an outbreak, be extra careful: During an outbreak, like with COVID-19, the immunocompromised have to take strict measures to ensure their safety. They should practice self-isolation and reduce interaction with other people during the course of the epidemics. This may not be easy, but it is the safest strategy, says Vabret. They should plan solutions to avoid having to go into crowded public places such as supermarkets, restaurants, and social events. The overall objective is to adapt your lifestyle to reduce your exposure to the virus.

More tips: Check out our article on how to boost the immune system for more detailed tips.

If youre immunocompromised, remember, its always better to be safe than sorry. Be responsible and make decisions that put yourself and your health first.

Read the original here:
What it means to be immunocompromised and the conditions that put you at risk of infection - Business Insider

Covid-19 and psycho-immunology of panic – Thrive Global

Weare living in a memorable time indeed.

Thisarticle is an exploration of one question: given the current situation, didyou reach out for more toilet paper or more connection?

Im sure youve had a thought or two about the toilet papersituation at this point. Its a global event. Ive come to see it assymptomatic of what Freud called a cornerstone that civilization requires toexist, i.e., the renunciation of instinct.

Toput it simply: Id. Primitive, instinctive, unsophisticated Id.

Freudsoriginal insight suggests that the sublimation of primitive aggressivetendencies is a pre-requisite for civilization. It is impossible to overlookthe extent to which civilization is built up upon a renunciation of instincthe noted. The repression of aggressive instincts is perhaps one of the mostimportant functions our ego has. An injured, or maladaptive ego (aswe say in clinical jargon), doesnt sublimate aggression well. Redirectedaggression or sublimated anything ideally turns into creativity and curiosity,by the wayboth a healthy thing.

Ascared human is not a creative, curious human.It doesnt get simpler. Most of us are familiar with the notion of the reptilianbrain, and currently, you can feel it right here in your gut PANIC. Themessage comes automatically from the survival part of the brain through ourbodily sensations, feelings, emotions and thoughts.

Itscreams: Hoard, protect, hide, cover. Mine!

Whatis furthermore unique during this time is that the message of uncertainty isofficial. The Covid-19s response team from the Imperial College in London,which is about as formal and authoritative as one can get, notes:

We, therefore, conclude that epidemic suppression is the onlyviable strategy at the current time. Thesocial and economic effects of themeasures which are needed to achieve this policy goal will beprofound However, we emphasize that it is not at all certain (emphasismine) that suppression will succeed long term; no public health interventionwith suchdisruptive effects on society has been previously attempted forsuch a long duration of time. Howpopulations and societies will respond remainsunclear(emphasis mine).

Thedefining characteristic of a traumatic event is perceivedhelplessness. Covid-19s imposition on the changes related to our day-to-day(look at Zoom stock) are less significant than the uncertaintyrelated to its outcome in the long term.

Thisuncertainty is evident in the questions that are elicited How long will itlast? When will things go back to normal? Can I (fill in the blank) whilethe epidemic is going on? Short of what authorities are describing aspreemptive personal hygiene measures in the social sphere, the truth is that theuncertain is greater than that which is certain now.

Thehuman brain particularly the amygdala does not like unknowns. But thatsbeside the point here. Let us get back to the toilet paper.

Toiletpaper. Toilet paper is panic, its primitive, its Id. What did we do for allthose years before we had any? I wonder! Its a well-known principle thatcharacter reveals itself under pressure. This principle has certainly applieditself in my own life; however, it is also true that many people may not haveexperienced the level of demand, uncertainty, and dread that Covid-19 elicits.The virus, therefore, has become an induced initiatory experience for most ofthe population.

Initiationinto what you ask. Stillness.

Onemust admit, however, that initiation into stillness implies a privileged pointof view. Our current social reality is that most of us are about to havematters made worse by this situation. Unfortunately, wrapping ourselves intoilet paper wont help.

Medical providers and emergency responders (all of whom willmost likely become ill) are running out of supplies and require donations towork.

Additionally,many are at risk of entering into a state of economic duress, which would becompounded by becoming ill: Oh, the medical bills if you end up needing thatrespirator!

Forthose who find themselves in the throes of economic duress compounded byillness or the fear of becoming ill, one word applies: Endure.

Itwill not help to fight the injustices of the system, or to try to make sense ofwhy airlines get bailouts while we cant pay our rent. We must pause, take aknee, and learn to calm our nervous systems down. When this is over, the resiliencewe have developed will allow us to flourish, and to take a stand for authenticindependence in our lives.

Thewisdom of political resistance applies here: Dont let the system get youdown. Trust me; Im an immigrant, and I know a thing or twoabout systemic pressures in this country.

Covid-19has not diverted the world from its path of economic inequality. On thecontrary, it has inflamed it. The clinical consequences are only one side ofthe problem. Im not proposing complacency about present inequalities far fromit. Rather, this is a call to see the situation as it immediately demands. Letus fight in one impossible battle at a time.

Letus attend further to the enemy at hand: fear itself.

Intrinsicto this situation and regardless of our economic status is the fear it produces.The brain here enters into a state of acute hyper-arousal triggering our mostbasic survival complex. This state supersedes our capacity for rationalexecutive functioning, e.g., understanding the contemplation being offered here.

Naturesdesign is quite sophisticated, after all, and when shit hits the fan weeither fight, run, or play dead. Crises unmask us, expose us and make us vulnerable.Such crises trigger every psychological defense available to us. And when thosefail? Dread sets in. You know the dark stuff.

Thebottom line is this: panic-buying, or pandemic-consumerism, is asymptomatic reflection of a nervous system gone astray. It isirrational behavior a mind confused and intensely reactive to itsprojections, primitive regression, and catastrophic thinking.

This survival strategy has obvious limits and misses the fact that the same environment that gave us the primitive drive, also gave us the pre-frontal lobe. However, we must decide to access it. Victor Frankl (someone the whole world should get acquainted with right about now if they havent yet) famously noted that:

Everything can be taken () but one thing: the last of thehuman freedomsto choose ones attitude in any given set of circumstances, tochoose ones own way.

Frankls was a human insight birthed within a concentration camp. Something similar was suggested in WWII as a morale campaign during the bombing in London hence the sign. Who would have thought that the British stiff-upper-lip could be used as a paragon of sanity for the time?

Butaccessing the pre-frontal cortex is not just a choice (it is that too). It is asystemic, whole-body, physiological event. It is a central nervous system state.And accessing this state, for almost all of us, requires training the mind-body.

Yousee, stillness and distraction dont go together. And for the most part, we areall very distracted. We have become accustomed to a way of life in which thevirtual domain outweighs our direct sensory experience of the ourselves and theworld. Social media and the world of virtual social interactions have made itso that the desired image of ourselves outweighs reality. Covid-19 is a realitytesting principle the world was not expecting.

Becausewe are habituated to the blinding pace of our current world slowing down willfeel initially like a shock. Ive seen this repeatedly in meditation retreats orin wilderness solos, where students sit by themselves in Nature for severaldays at time. These practices arethousands of years old, and have been understood for millennia to havetremendous psychological and spiritual significance.

Ihave certainly experienced this myself.For me, it usually takes about three days of sitting for the staticwhite noise of the city to go away. There is a ringing in the ears that all ofa sudden lets up, allowing me to yield and relax; It is something hard toexplain; however, it happens to most of us, and nowadays, its measurable in alab.

However,lab measurements of brain wave activities during meditation practice are notthe point. Reactionary and aggressive protest around stillness is the point. Italmost sounds too benign to be true: defense-against-silence asthe core issue. But I propose that it is.

BlaisePascal noted famously that Allof humanitys problems stem from one persons inability to sit quietly in aroom alone.

Idont know about all, but I certainly know about most. In addition,the incapacity for stillness adds to all the other problems most of thetime, because an anxious mind projects fear everywhere and regresses intoneurotic self-preservation, as we discussed before.

Allof this ends up compromising the immune system. How do I know this? Becausestress kills. And if it doesnt kill you, it will certainly injure you. Morespecifically, your response to your fear will effect your immune system.

Fearis but a primitive, startle-based survival impulse that, at its best, serves asan orienting function. You want to be able to alert to the danger and be ableto respond to it as the situation demands. But anticipating the punch, blockingit before it comes, countering before the opening is there all miss thewisdom of timing things. Anticipatory anxiety is a fear-based reaction that iscurrently making the crises worse. The epidemiology of Covid-19 is irrelevantinsofar as the incapacity to sit still with uncertainty goes. More importantly,it misses the insight that this is controllable, for each individualthrough the practice of stillness.

EmilyLandon, the chief infectious disease epidemiologist at the University ofChicago Medical School, touched upon this when she noted that the healthy andoptimistic among us will doom the vulnerable. She went on to say, that wewould be right to feel that the strategy of saving the world by doing nothingwas anti-climactic.

However, doing nothing ishardly as easy as it sounds.

It remains true that beforethis virus, we measured the value of life solely by doing more and more. Bemore efficient, more productive, more successful. At what cost? At the cost ofall our relationships, the eco-system included. Greed and ambition have nolimits, are always rewarded, and bailed out when they fail.

It will take courage not tobe defined by the pathological lack of empathy that drives so much of thissystem as it stands.

We text rather than call,post rather than engage, and push the like button because its just so damneasy. All of which contradicts the existential reality that the deepest communicationis mostly non-verbal! Were not built to look all day at the little screen;were made to look at each other. Babies and mothers know this for certain; nevertheless,it is true for all of us. We were all infants once, and we will never outgrowthat mirroring. Thank goodness!

As a mental health professional,I am stunned at the lack of public initiatives that address the primacy ofmental health in a moment like this. We all need the medical system to work. JayashriKulkarni, a psychiatry professor at Monash University in Melbourne, notedrecently: There is a prevailing belief that in any crisis you deal with thephysical issues first, then the mental health issues much later. I challengethis view because we need the public to be robust mentally to deal withthe challenges ahead (my emphasis).

A psychology of endurancerequires us to trainourmindsto desire what thesituation demands, as Seneca noted about 2000 years ago. The current crisesrequires balance and patience from us. It requires not to get ahead ofourselves, and not to amplify fear and dread.

Sittingstill with uncertainty is as simple as it sounds but not as easy you think. Allyou have to do is sit down, turn everything off that habitually distracts you,and breathe. Close your eyes if you want it doesnt matter. Just. Sit. Still.I challenge you to do it! Greater good will come from building this resiliencethan anything else you can do right now. As a good friend of mine and inspiring artist wrote recently:

We are not in a hurry

We need not run

We are the ants busy building ourmound

We are the trees dried and chappedstanding firm

We are here for what comes

We are the grass that laid our seedlong ago

We are ready for this moment

We are always ready

We know what to do

We have always known what to do

We need not run

-RobertBellows

References:

https://www.washingtonpost.com/health/2020/03/20/emily-landon-coronavirus/

https://www.cnbc.com/2020/03/20/coronavirus-tips-for-protecting-your-mental-health-during-quarantine.html

Seneca

Victor Frankl., Mans Search forMeaning

See the rest here:
Covid-19 and psycho-immunology of panic - Thrive Global

Too Much Salt May Lower Your Ability to Fight BacteriaHere Are Four Ways to Help Boost the Immune System – Newsweek

A high-salt diet can weaken the immune system and leave the body vulnerable to certain types of infection, according to immunologists writing in the journal Science Translational Medicine.

They investigated the effect a diet high in salt had on the immune system, first in mice and then in humans. The mice on saltier diets suffered more severe bacterial infections, while the humans displayed pronounced immune deficiencies.

"Our findings suggest that the daily recommended intake of 5 to 6 grams of salt should not be exceeded by much," corresponding author Christian Kurts, from the Institute of Experimental Immunology at the University of Bonn, told Newsweek.

"Lowering salt actually does not invigorate the immune system according to our work," he said. "The recommended salt amount seems to be good for the immune system."

Read more

Kurts and his team compared the immune response of two groups of miceone fed a high-salt diet and the other a normal-salt dietto a urinary tract infection (UTI) caused by uropathogenic E.coli (UPEC).

The researchers found UTIs were aggravated by the high-salt diet, with the mice on these diets showing four to six times more UPEC than the control group. Recovery times also took longer; results that the author's attribute to hormones released to help the body excrete excess salt (glucocorticoids), which have the added effect of suppressing the immune system.

High-salt diets can also cause accumulation of urea in the kidney, which may suppress the antibacterial capabilities of white blood cells, the researchers suggest.

When the mice were infected with listeria, those on the saltier diet experienced more severe reactions to the bacteria. The researchers counted between 100 and 1,000 times the number of pathogens in the spleens and livers of mice in the high-salt category.

To investigate further, the researchers placed 10 volunteers on a high-salt diet for a week. This involved taking three tablets a day that added up to an extra 6 grams of salt to their dietequivalent to what you might find in 1.5 to two large fast food meals.

By the end of the week, the volunteers were showing signs of immunodeficiency. While numbers of neutrophils, a type of white blood cell, remained stable, their ability to fend of bacteria was lower than at the start of the study.

Concluding, the team say that because Western diets are now high in salt, "these findings reveal that people might be making themselves more vulnerable to bacterial infections."

Kurts said the best way people can boost the immune systems generally is to ensure they have had all appropriate vaccinations. "Apart from that, measures that are healthy in general are good also for our immune system: vitamins, moderate exercise, avoid junk food."

Below are four ways people can boost their immune system through diet and lifestyle.

There is a growing body of scientific evidence that suggests a healthy lifestyle revolving around good diet, exercise, sleep and reducing stress can help the immune system to run more efficiently.

In contrast to a high-salt diet, eating a healthy balanced diet consisting of plant-based fiber can support the body's "good" bacteria, which in turn may help the immune system, explained Dr. Louisa James, Lecturer in Immunology at Queen Mary University of London, U.K.

"The trillions of bacteria in our gut work in exquisite symbiosis with our immune system," James told Newsweek. "They stimulate our immune cells to make antibodies, they secrete by-products which maintain specialised immune cells that regulate our immune system and they even produce antibacterial and antiviral chemicals that can fight pathogens on our behalf."

Contrary to popular belief, there is limited evidence to show taking vitamin C supplements helps to fend off the flu, unless you are deficient in the first place. However, an analysis of 29 studies did suggest taking vitamin C supplements could reduce the amount of time a person infected with the common cold displayed symptoms, particularly if they were active.

James instead emphasizes the importance of vitamin D, which we mostly recieve through sunlight, in regulating the immune system.

"Vitamin D is essential for bone health but is also important for regulating our immune system," said James, pointing to research published in 2017 that found vitamin D supplements were a safe way to help protect people deficient in the vitamin from respiratory infections.

Vitamin D may help the body's macrophagesa type of white blood cellfunction better, while there is some evidence that vitamin E helps the T cells, "the other side of the immune system," Professor Janet Lord, Director of the Institute of Inflammation and Ageing at the University of Birmingham, U.K., told Newsweek.

Daniel Davis, Professor of Immunology at Manchester University, U.K., is skeptical about the role of nutrition on the immune system, telling Newsweek: "Obviously nutrition is important, certainly at some level, but it also seems to be very personal.

"The way that we respond to this or that food seems to vary hugely from one person to the next, and understanding why that is and being able to come up with clear health advice about nutrition is only just beginning to be done."

Davis, whose book The Beautiful Cure explores the immune system and the body's ability to fend off disease, points to the sheer number of books on nutrition and different dietary approaches, "which tells you something about the fact that we don't really know what's going on."

Another factor that research suggests could influence the body's response to infection is sleep.

Immune cells have adhesion receptors on their surface, explained James. These receptors (called integrins) enable them to move around the body and interact with other cells. However, levels can fluctuate depending on the presence of certain stress-related hormonessuch as adrenaline and noradrenaline.

In a paper published in the Journal of Experimental Medicine in 2019, scientists in Germany revealed levels of these hormones change throughout the day, dipping when we sleep. According to the study's authors, sleep loss can reduce levels of receptors on immune cells, which in turn may impair their ability to operate as effectively as they would under normal circumstances.

In contrast, regularly having a good night's sleep can enhance the immune system by improving immune cells' ability to attach to the targets.

Twin studies and laboratory tests have also emphasized the role of sleep in the proper functioning of the immune cells; showing shorter sleep durations are associated with a depressed immune system, while getting rest offers the immune system a chance to regroup when infection risk is low.

However, Davis says it can be hard to disentangle the effects of a lack of sleep from other factors, such as different eating times and stress.

"One thing that does seem to really affect the immune system is chronic stress," said Davis, and it relates to the hormone cortisol.

Levels of cortisol naturally peak and trough throughout the day, for example, rising as the body gets ready to wake up. The hormone plays an important role in the body's flight or fight response and remains at elevated levels when we are confronted by a source of stress.

"When you're in a state of fight or flight, your body is dealing with this current emergency and a lot of other bodily processes are dampened down," said Davis. These bodily processes include the immune system.

"This is fine in the short-termstress is not something to be entirely avoided. But if you have chronic stress and cortisol levels stay very high, it becomes a problem and makes you more susceptible to the flu and other viruses."

The obvious answer to this is to create an environment and lifestyle that minimizes sources of chronic stress, but Davis warns there is very little solid evidence that practices known to reduce stress can directly boost the immune system. The research is not there yet, he said.

"One thing that's becoming clear is that physical activityexerciseis a really powerful influencer of the immune system," said Lord, who co-authored a study investigating the immune system of cyclists aged 55 to 79. The researchers found their immune system more closely resembled that of a twenty- or thirty-something than someone their own age.

Movement gets the blood pumping and gives immune cells the chance to circulate the body. "Good circulation is essential to allow our immune cells to migrate throughout our body and perform their essential roles in immune surveillance," said James.

A key part of the immune response is inflammation and people who exercise regularly appear to have a more efficient immune system that is better at turning on and turning off inflammation, Lord explained, but warned that extended periods of sitting could undo the benefits.

"Sitting is the new smoking," she said. "We're hunter gatherers in a modern society. We haven't evolved to be sitting around all day."

Her advice is to not sit down for longer than an hour, even if it means walking up and down the stairs or investing in a standing desk. When it comes to physical activity, it doesn't matter what it isjust as long as you do it.

"Don't punish yourself by doing some form of physical activity you don't like. You like gardening, get out and do some gardening. If you like a brisk walk, do that," said Lord. "Just do something."

Follow this link:
Too Much Salt May Lower Your Ability to Fight BacteriaHere Are Four Ways to Help Boost the Immune System - Newsweek

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines – PharmiWeb.com

INDIANAPOLISandOXFORD, England,March 31, 2020/PRNewswire/ --Eli Lilly and Company(NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration will study up to four novel preclinical targets identified by Sitryx that could lead to potential new medicines for autoimmune diseases.

"AsLillyseeks to develop new and unique medicines for people suffering with autoimmune diseases, we are actively exploring a variety of scientific approaches both in our own labs and with external partners," saidAjay Nirula, M.D., Ph.D., vice president of immunology atLilly. "Regulating the metabolism of immune cells is a promising approach to treating these diseases, and we look forward to working with the talented researchers at Sitryx to advance their novel immunometabolism targets."

"We are excited to partner withLilly, one of the global leaders in the field of immunology, to pursue the discovery of novel targets and the development of innovative therapies for autoimmune and inflammatory diseases in the fast-emerging area of immunometabolism," saidNeil Weir, Ph.D.,chief executive officer of Sitryx. "This agreement is transformational for Sitryx and further validates the strength of our scientific expertise and that of our Founder network and the potential for Sitryx to become a leader in this field."

Under the terms of the agreement, Sitryx will receive an upfront payment of$50 millionandLillywill make a$10 millionequity investment in Sitryx. Sitryx will be eligible to receive potential development milestones up to$820 million, as well as commercialization milestones and royalty payments on potential sales in the mid- to high-single digit range. In return, Sitryx will grantLillyan exclusive, worldwide license to develop and commercialize up to four novel immunometabolism targeted therapeutics, including Sitryx's two lead projects.Lillyand Sitryx will establish a 5-year research collaboration to support the development of the therapeutics, with Sitryx responsible for drug discovery, whileLillywill fund and manage the clinical development and commercial phase of the collaboration.

This transaction is subject to customary closing conditions. The transaction will be reflected inLilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change toLilly's 2020 non-GAAP earnings per share guidance as a result of this transaction.

About SitryxSitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism;Houman Ashrafian,Luke O'Neill,Jonathan Powell,Jeff Rathmell,Michael RosenblumandPaul Peter Tak. Together they have published more than 1,000 papers in the field, making multiple key breakthroughs in our understanding of how critical energetic status is to the behavior of immune cells and in the broader field of immunology. In 2018, Sitryx raised$30 millionSeries A funding from an international syndicate of specialist investors includingSV Health Investors,Sofinnova Partners,Longwood Fundand GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered inOxford, UK. For more information, please visitwww.sitryx.com.

AboutEliLillyand CompanyLillyis a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe,Lillyemployees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more aboutLilly, please visit us atwww.lilly.com. C-LLY

LillyForward-Looking StatementThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration betweenLillyand Sitryx, and reflectsLilly's current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee thatLillywill realize the expected benefits of the collaboration, or that the collaboration will yield commercially successful products. For a further discussion of these and other risks and uncertainties that could cause actual results to differ fromLilly's expectations, please seeLilly's most recent Forms 10-K and 10-Q filed with theU.S. Securities and Exchange Commission.Lillyundertakes no duty to update forward-looking statements.

See the original post here:
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines - PharmiWeb.com

Heat Biologics Announces Formation of COVID-19 Advisory Board – Yahoo Finance

DURHAM, NC / ACCESSWIRE / April 1, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines, including one for coronavirus COVID-19, announced today the formation of its COVID-19 Advisory Board (CAB) with four key appointments: Justin Stebbing MD, PhD, Raymond Pickles, PhD, Natasa Strbo MD, DSc, and Lanying Du, PhD.

Heat's COVID-19 Advisory Board was established with leading thought leaders to propel Heat's COVID-19 vaccine and COVID-19 diagnostic programs. The combined Advisory Board has expertise in areas of coronavirus and related respiratory virus biology and infection, immunotherapy, and vaccines. Heat recently announced a research collaboration with the University of Miami Miller School of Medicine to develop a vaccine leveraging Heat's proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19. Under a separate collaboration with the University of Miami Miller School of Medicine, Heat also intends to develop a proprietary COVID-19 point-of-care diagnostic test.

The CAB members include:

Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "We are thrilled to have attracted leading experts in immunotherapy and vaccines to support Heat as we continue to develop Heat's COVID-19 vaccine and COVID-19 diagnostic programs. We look forward to working closely with the CAB to advance our programs to help combat the current COVID-19 pandemic."

Justin Stebbing MD, PhD, is a Professor of Cancer Medicine and Oncology, Consultant Oncologist, at the Imperial College and Imperial College Healthcare NHS Trust. Professor Justin Stebbing specializes in a range of malignancies, their treatment with immunotherapy (breast, GI and lung and clinical trials), having originally trained in medicine at Trinity College Oxford, where he gained a first-class degree. After completion of junior doctor posts in Oxford, he undertook training and a residency program at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals. Professor Stebbing's original PhD research investigated the interplay between the immune system and cancer; he was appointed a senior lecturer in 2007, and a Professor in 2009. Professor Stebbing has published over 600 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing regularly for national newspapers and presenting new data on optimal cancer therapies at the major international conferences.

Raymond Pickles, PhD, is an associate professor in the Department of Microbiology and Immunology within the UNC School of Medicine. His research is focused on how viruses infect the respiratory tract of humans and other animal species and why highly pathogenic viruses often result in more severe airway disease. He has 30 years of experience working with models of the respiratory tract and has used these models to understand infection outcomes with Respiratory Syncytial Virus (RSV), Adenoviruses, newly emerging avian influenza viruses, and newly emerging coronaviruses including SARS. He received his PhD from the University of Cambridge before completing Post-Doctoral Studies in the Division of Pulmonary Medicine at UNC-Chapel Hill

Natasa Strbo MD, DSc, is an assistant professor of microbiology and immunology at the University of Miami, Miller School of Medicine. Dr. Strbo is also a co-developer of Heat's gp96 platform and has spent many years advancing the platform as a vaccine against HIV and malaria. Dr. Strbo's current research is focused on devising a novel strategy for achieving as complete a protection as possible, the ultimate goal being the future development of an efficacious heat shock protein (HSP) gp96-Ig vaccine against HIV, malaria, ZIKA, CMV, COVID-19 and other emerging infectious diseases. Dr. Strbo was the recipient of a Miami CTSI KL2 Award (2013-2016) to study vaccine-induced immune responses in the reproductive tract of HIV-infected humanized mice and she was also awarded the University of Miami Glaser Award for 2016 to further develop HIV vaccine technology.

Story continues

Lanying Du, PhD, is a Member at the New York Blood Center (NYBC) and is the Head of Viral Immunology Laboratory at the Lindsley F. Kimball Research Institute of NYBC. Dr. Du's research focuses on the development of effective and safe vaccines and therapeutic agents to prevent and treat emerging and reemerging infectious diseases caused by coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV), Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and other coronaviruses with pandemic potential, influenza viruses, as well as flaviviruses, including Zika virus and dengue virus. Dr. Du's research also focuses on the study of pathogenic mechanisms of these viruses, based on which to design novel vaccines and therapeutic antibodies. Her research tools include rational design of novel vaccines and therapeutics, mRNA technology, drug screening, antibody production and evaluation.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer and other diseases using its proprietary gp96 platform to activate CD8+ "Killer" T-cells. Heat has completed enrollment in its Phase 2 clinical trial for advanced non-small cell lung cancer with its gp96-based HS-110 therapeutic vaccine. HS-110 is the company's first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells. Heat Biologics has also launched a program in collaboration with the University of Miami to develop a vaccine designed to protect against the COVID-19 Coronavirus. Heat has numerous other pre-clinical programs at various stages of development. For more information, please visit http://www.heatbio.com.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements such as the support to be received by the SAB members with respect to Heat's continued development of its COVID-19 vaccine and COVID-19 diagnostic programs and advancing Heat's programs to help combat the current COVID-19 pandemic. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the contribution of the SAB, the ability of Heat together with researchers at the University of Miami to develop a proprietary COVID-19 point-of-care diagnostic test, the ability of Heat's vaccine platform to provide protection against COVID-19, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K for the year ended December 31, 2018 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

CONTACT:

David Waldman+1 919 289 4017investorrelations@heatbio.com

SOURCE: Heat Biologics Inc.

View source version on accesswire.com: https://www.accesswire.com/583405/Heat-Biologics-Announces-Formation-of-COVID-19-Advisory-Board

Continued here:
Heat Biologics Announces Formation of COVID-19 Advisory Board - Yahoo Finance

REPEAT – QUESTCAP TO INVEST $1 MILLION WITH SUNNYBROOK RESEARCH INSTITUTE TO ESTABLISH THE SUNNYBROOK TRANSLATIONAL RESEARCH GROUP FOR EMERGING AND…

TORONTO, April 02, 2020 (GLOBE NEWSWIRE) --

QuestCap Inc. (QuestCap or the Company) (CSE: QSC; OTCMKTS: COPRF; FRA: 34C1) is pleased to announce an investment of $1 million in the Sunnybrook Research Institutes COVID-19 research. With these funds, Sunnybrook will establish the Sunnybrook Translational Research Group for Emerging and Respiratory Viruses (SERV) and QuestCap will receive a 3.5% royalty on any revenues earned by Sunnybrook from the commercialization of any of the research done by SERV.

Led by infectious diseases physician and microbiologist Dr. Samira Mubareka, SERVs work will focus on three crucial streams of research: vaccines and therapeutics, virus biology and transmission prevention. Dedicated investment in SERV means Dr. Mubareka and her team will be able to accelerate the pace of further research into COVID-19 at a crucial time.

Dr. Lawrence Steinman and Mike McCarthy Appointed as Advisors

QuestCap is pleased to announce the appointment of Dr. Lawrence Steinman and Mike McCarthy to the board of advisors. Dr. Lawrence Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011.

Mike McCarthy has more than 14 years of experience with the Ontario Ministry of Health and Long-Term Care and 24 years in health policy and delivery. He was appointed Senior Policy Advisor to the Progressive Conservative Minister of Health of Ontario, advising on physician, nursing and primary care, public health, laboratories, OHIP, organ transplant, HIV and blood issues. In 2003, he provided strategic support and counsel to the government of Ontario during the SARS outbreak.

Lawrence Steinman stated that, The Sunnybrook technology will be a key tool for the development of both powerful and safe vaccines against COVID-19, and for the development of point of care and even home diagnostics to test whether one is immune to the COVID-19 virus. Those who are immune can return to work and can provide safe and needed duties to the community. It would be especially important to know if you are a health care worker, grocer or delivery person whether or not you have immunity. You could then be safe and carry on as a SuperWomen or SuperMan in these times, knowing you are immune! Mike McCarthy adds I look forward to advising QuestCap in its visionary efforts to bring innovative testing and vaccine technologies to Canada and the world to combat COVID-19.

The Company has granted 500,000 stock options to Mr. Steinman pursuant to the Companys stock option plan. The stock options shall vest in four equal instalments every three months such that all stock options fully vest by the date that falls 12 months from the date of grant and may be exercised at a price of $0.305 per common share for a period of five years from the date of grant. This grant of options is subject to the approval of the Canadian Securities Exchange.

Sunnybrook Translational Research Group

Sunnybrook has been at the global forefront of the COVID-19 pandemic since the first Canadian case was identified, both clinically and on the research front. Dr. Mubareka, along with clinical microbiologist Dr. Robert Kozak and a team of close collaborators, has led Sunnybrooks research response efforts since the earliest days of the pandemic. Their work has been globally significant, leading to early implementation of a hospital-based COVID-19 test. Most crucially, on March 10, 2020, their team isolated the agent responsible for the ongoing outbreak of COVID-19. The isolated virus is helping researchers in Canada and elsewhere to develop better diagnostic testing, treatments and vaccines, and gain a better understanding of the viruss biology, evolution and clinical shedding.

This is extremely time-sensitive research, says Dr. Mubareka. As a scientist on the frontlines, I have seen the devastation this virus can cause. We all feel the effects of physical distancing as our lives are fundamentally changed. This is why support from our community is so important right now. The more we understand how this virus behaves, the better we can limit its spread as we race to find a treatment or vaccine. This investment will be put to work immediately toward our human and operational funding needs to rapidly accelerate research into COVID-19.

Story continues

Now is the time to dedicate as many resources as possible to stopping the spread of this highly contagious virus, explains Dr. Andy Smith, Sunnybrooks President and CEO. On behalf of Sunnybrook, I would like to extend my deepest thanks to QuestCap for stepping up with this inspiring investment. Your support will have a direct impact on the lives of countless people in our communities, across Canada and around the world.

With these crucial tools in hand, QuestCap saw an opportunity to give this research a major boost at a critical juncture. As countries grapple with the effects of COVID-19, there has been a collective global effort to help minimize the impacts of this deadly virus, says Stan Bharti, Co-Chairman of QuestCap. QuestCap, through its investment platform, is looking to do its part by providing a critical investment to help fund the vital research being conducted by Dr. Mubareka, Dr. Kozak and their teams.

The investment to Sunnybrook will help researchers in Canada and across the world develop better diagnostic testing, treatments and vaccines, and gain a better understanding of SARS-CoV-2 biology, evolution and clinical shedding for the development of commercial applications (Commercial Applications). As consideration for its investment, QuestCap will receive a 3.5% royalty on any revenue earned by Sunnybrook from the any Commercial Applications resulting from the research conducted by SERV.

At a time of global uncertainty as COVID-19 continues to devastate people, families and entire countries, the urgency of research has never been greater, says Dr. Kullervo Hynynen, Vice President of Research & Innovation at Sunnybrook. Yet, often times, there simply isnt enough funding for research. I am deeply grateful to QuestCap for this clear statement on supporting the power of research to save and change lives.

About the Research

SERV is a three-pronged COVID-19 research response program, consisting of the following critically important areas of focus:

1. Virus biology (genomics): Identifying the genetic sequence of a virus is an essential step for identifying key targets for treatments and vaccines. It also tells the story of origin and its relation to other viruses. This approach provides precision genomic data, which will be essential for outbreak investigation. Funds for SERV allow Sunnybrook scientists to turn around whole genome viral sequences at the site of care: Sunnybrook.

2. Vaccines and therapeutics: Our ability to identify and isolate the virus that causes COVID-19, based on samples from infected patients, allows us to collaborate on antiviral research and conduct our own vaccine and transmission work. With SERV, Sunnybrook will share our findings about the virus within the Canadian research and diagnostic community, thereby driving further innovative solutions to the COVID-19 pandemic.

3. Transmission prevention: As part of a World Health Organizations effort to evaluate risk to health-care workers of providing certain support measures, such as high-flow oxygen use, Sunnybrook is building a simulation space for live virus experiments using mannequins with funds for SERV. This is important because protecting care providers is key to preventing the spread of the virus within hospitals.

About Lawrence Steinman

Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on antigen specific tolerance in autoimmune disease and in gene therapy for degenerative neurologic diseases. He has elucidated what provokes relapses and remissions in multiple sclerosis (MS). He is taking forward a pivotal clinical trial with antigen specific tolerization therapy for type 1 diabetes. He serves as attending neurologist at Stanfords Lucille Packard Childrens Hospital. Steinman is an elected member of the US National Academy of Sciences and the National Academy of Medicine.

Steinman was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohns disease. Tysabri has been taken by over 200,000 individuals with MS.

Dr. Steinman graduated from Dartmouth College, Magna Cum Laude in Physics. His MD is from Harvard Medical School. He was a post-doctoral fellow in chemical immunology fellow at the Weizmann Institute of Science. After neurology residency he remained on the faculty in 1980. He has received numerous honors, including the John M. Dystel Prize in 2004, the Javits Neuroscience Investigator Award from the NINDS twice, the Charcot Prize in MS research, and the Cerami Prize in Translational Medicine. Steinman is a member of both the National Academy of Sciences, and the National Academy of Medicine.

Dr. Steinman co-founded several biotech companies, including Neurocrine, Atreca, 180 Therapeutics, and Tolerion. He was a Director of Centocor from 1988 until its sale to Johnson and Johnson.

About Mike McCarthy

Mike is widely recognized across Canada as a stellar health care advocate and system expert. As a volunteer Vice-President of the Canadian Hemophilia Society, Mike was the national spokesperson for Canadians infected by blood tainted with Hepatitis C. His tireless efforts resulted in a landmark $2 billion settlement with the federal government in 2006, and the Queens Golden Jubilee Award presented by the Governor General of Canada.

Presently Mike is a Principal at Grosso McCarthy and provides counsel to clients in both the not-for-profit and for-profit sectors. He helps clients navigate provincial, federal and international governments at the levels of the civil service and elected officials. Mike has also been on the front lines of health care, working for 18 years as a psychiatric nurse.

As a principal with Grosso McCarthy, Mike builds on more than 14 years of experience with the Ontario Ministry of Health and Long-Term Care and 24 years in health policy and delivery. He was appointed Senior Policy Advisor to the Progressive Conservative Minister of Health of Ontario, advising on physician, nursing and primary care, public health, laboratories, OHIP, organ transplant, HIV and blood issues.

In 2003, he provided strategic support and counsel to the government of Ontario during the SARS outbreak.

About QuestCap

QuestCap is an investment company that seeks to enhance shareholder value over the long term by opportunistically making various investments that may include, without limitation, the acquisition of equity, debt or other securities of publicly traded or private companies or other entities, financing in exchange for pre-determined royalties or distributions and the acquisition of all or part of one or more businesses, portfolios or other assets.

For additional information, please contact:

G Scott Moore

Co-Chairmansmoore@forbesmanhattan.com1-416-861-5903

Media contact:

Wynn TheriaultThirty Dash Communications34 King St East #400Toronto M5C 2X8416.710.3370

Cautionary Note Regarding Forward-lookingInformation

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the investment with SERV; the grant of options; and Sunnybrook and the appointment of advisory board members. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Read more from the original source:
REPEAT - QUESTCAP TO INVEST $1 MILLION WITH SUNNYBROOK RESEARCH INSTITUTE TO ESTABLISH THE SUNNYBROOK TRANSLATIONAL RESEARCH GROUP FOR EMERGING AND...

Carterra to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC) – Technology Networks

Carterra Inc., specialists in high-throughput antibody screening and characterization tools, and La Jolla Institute for Immunology (LJI) have announced that they will use Carterras proprietary LSA platform to screen hundreds of antibodies in just a few days, allowing CoVIC to move therapeutic candidates to the clinic as early as this summer.

La Jolla Institute for Immunology (LJI) has been awarded a $1.73 million grant by the Bill & Melinda Gates Foundation to establish a Coronavirus Immunotherapy Consortium (CoVIC) as part of the foundations global efforts to stem the tide of the current coronavirus outbreak, the Institute announced yesterday. Antibody therapies are often the first novel therapies advanced for an emerging infectious disease.

Headquartered at LJI, CoVIC will serve as a clearinghouse to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2 and to accelerate the research pipeline to provide immunotherapeutics in order to protect vulnerable individuals from severe manifestations of COVID-19 in all parts of the world, including low-resource settings.

This effort is being funded as part of the COVID-19 Therapeutics Accelerator launched in early March by the Gates Foundation, Wellcome, and Mastercard. The Accelerator provides fast and flexible funding at key stages of the development process to de-risk the pathway for drugs and biologics to prevent and treat COVID-19.

The effort is led by Erica Ollmann Saphire, Ph.D., a professor in LJIs Center for Infectious Disease and Vaccine Research, who draws on her broad research experience guiding the development of antibody drugs and galvanizing a global research coalition that helped define which therapeutic antibodies effectively combat disease in humans infected with Ebola virus.

We are thrilled that Carterra will provide full antibody characterization data using affinity measurements and, potentially more importantly, ultra-high resolution information of the epitopes, says Dr. Ollmann Saphire. Knowing how well these antibodies bind to the target is important but understanding their mechanism of action and how different antibodies can complement each other will determine what ends up in the clinic.

Traditional antibody discovery requires a primary screen of ever-expanding antibody libraries. Only a small group of candidate antibodies are then characterized on traditional, low-throughput, low-resolution biosensor tools which provide real-time readout of the binding profile. This workflow runs the risk that potential drug candidates could be missed or that the process of candidate selection could be exceedingly long.

Carterras LSA is turning that model on its head by enabling the high-resolution analysis of entire libraries, combining screening and characterization into one seamless step, thereby minimizing the risk of missing a potent therapeutic candidate. The LSAs dramatic throughput condenses months of work into days. Infectious diseases are ideal for leveraging the power of the LSA platform as evidenced in recent studies of Yellow Fever and Ebola where the LSA helped elucidate the immunity of survivors.

Additionally, the LSA platform offers investigators the most resolved view of the epitope the location an antibody binds to its target. An epitope is an innate property that cannot be changed and must be discovered empirically. The LSA is the only technology that enables characterization of epitope binding at the full library level.

The world is in need of a solution to COVID-19, says Josh Eckman, Carterras Chief Executive Officer. Were honored to be the provider of high-throughput antibody screening and characterization data to CoVIC. They have the most ambitious research goals and aggressive timelines. The Carterra LSA is the right tool at the right time.

Visit link:
Carterra to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC) - Technology Networks